Sanofi appoints new leaders to Executive Committee and announces
future Chair of EUROAPI
Sanofi appoints new leaders to Executive
Committee and announces future Chair of EUROAPI
- Viviane Monges joins Sanofi as Chair of the Supervisory Board
of EUROAPI
- Roy Papatheodorou appointed EVP, General Counsel and Head of
Legal, Ethics & Business Integrity
- Brendan O’Callaghan appointed EVP, Global Head of Industrial
Affairs
Paris (France)
– July
29, 2021 – Karen Linehan and Philippe Luscan, who
have led Legal, Ethics & Business Integrity (LEBI) and
Industrial Affairs at Sanofi for the last 14 and 13 years
respectively have decided to retire. Karen will retire on December
31, 2021 and Philippe later in 2022. Sanofi has appointed Roy
Papatheodorou and Brendan O’Callaghan as their respective
replacements, joining the company’s Executive Committee.
Additionally, Viviane Monges will join EUROAPI,
a future leading European company dedicated to the development,
production, and marketing of active pharmaceutical ingredients
(API), as an independent non-executive Chair of the Supervisory
Board. She will serve as Chair of the Board of Directors upon
transformation of EUROAPI into a société anonyme, in compliance
with applicable corporate governance regulations.
Together, these appointments underscore the
company’s strategy to further increase the diversity and cultural
backgrounds of the executives leading Sanofi’s modernization.
“These new appointments, a mix of internal
promotion and newcomers to our company, bring three highly
qualified international leaders with world-class pharma expertise,
and a passion for engaging and leading teams across large
organizations. Brendan and Roy will be a great addition to our
Executive Committee,” said Paul Hudson, Chief Executive Officer at
Sanofi. “Also, Viviane, with her truly international experience
working with companies both in the private and public sectors will
be breaking new ground as chair of a future French company that is
set to become one of the world’s leading API companies. I thank
both Philippe and Karen for their many contributions over the
years.”
Viviane
Monges, independent non-executive Chair of
the Supervisory Board
Viviane Monges’ appointment is with immediate
effect. A French national, Viviane’s career has spanned across
several industries. She was CFO of the Business Excellence Division
at Nestlé. Prior to that, she spent nearly two decades leading
financial operations in three pharmaceutical companies. She served
as Group CFO at Galderma S.A., a multinational dermatology company.
She was EMEA CFO and then Global CFO of the OTC Division at
Novartis. At Wyeth Pharmaceuticals/Pfizer she served as CFO of the
Global Pharma Business unit. She also worked for Agence
France-Presse from 1990 to 1995.
She is currently an independent Director at
several pharmaceutical companies: UCB, Novo Holdings, DBV
Technologies, ADC Therapeutics, and Pharvaris. She also served on
the Board of Idorsia from 2018 to 2021.
Roy
Papatheodorou, Executive Vice President,
General Counsel & Head of Legal, Ethics &
Business Integrity
(LEBI)
Roy Papatheodorou, with dual Cypriot and Italian
nationalities, will take over the role of Sanofi’s General Counsel
and member of the Executive Committee on February 1, 2022. He will
replace Karen Linehan who will be retiring from Sanofi at the end
of 2021 after a long and successful career in the company. Roy
joins Sanofi from Novartis, where he is the General Counsel of
Novartis Pharmaceuticals. Roy brings a wealth of experience in
leading global and diverse high performing teams, having also
headed the Legal Transactions team at Novartis and having
previously been the General Counsel of the Actavis Group, one of
the largest generic companies at the time. He started his career at
international law firm Linklaters, where he specialized in
international M&A, corporate, and private equity based in
London, with time also spent in Russia and Brazil.
Brendan O’Callaghan, Executive Vice
President, Global Head of
Industrial Affairs
Brendan O’Callaghan, an Irish citizen, will
become the new Global Head of Industrial Affairs and member of the
Executive Committee as of October 1, and will take over from
Philippe Luscan who will be retiring from Sanofi after 32 years of
dedicated service to the company. Brendan is currently Sanofi’s
Global Head of its Biologics Platform and the Industrial Affairs
head of its Specialty Care portfolio. He has been responsible for
the development and acceleration of Sanofi’s biologics
manufacturing capacity and is leading world class manufacturing
sites like Framingham (recently awarded with the “Facility of the
Year” for its digitally enabled continuous biomanufacturing
facility). Brendan joined Sanofi in 2015 from Merck where he had
served as Head of Biologics and later Vice President of their EMEA
Operations after a few years working at Schering-Plough.
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare diseases and the millions with
long-term chronic conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe.
Media Relations
Contacts Ashleigh
Koss Tel: +1 (908)
205-2572 Ashleigh.Koss@sanofi.com
Sandrine
Guendoul Tel.: +33
(0)6 25 09 14
25 Sandrine.Guendoul@sanofi.com
Investor Relations Contacts ParisEva
Schaefer-JansenArnaud DelepineNathalie Pham
Investor Relations Contacts North AmericaFelix
LauscherFara BerkowitzSuzanne Greco
Tel.: +33 (0)1 53 77 45
45 investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact
Sanofi Forward-Looking Statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of
the foregoing could also adversely impact us. This
situation is changing rapidly and additional impacts may
arise of which we are not currently aware and may exacerbate other
previously identified risks. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2020. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024